Replay partners with MD Anderson’s Katy Rezvani, heads to clinic with new TCR NK cell company
Hub-and-spoke company Replay has launched a new cell therapy company called Syena, co-founded by NK cell leader Katy Rezvani of the University of Texas MD Anderson Cancer Center.
Syena plans to put Rezvani’s T cell receptor natural killer, or TCR NK, cell therapies into a Phase I trial in the second quarter of the year. That would make it the first to bring a TCR NK cell therapy into the clinic, Rezvani told Endpoints News. Rezvani added that they’re working on an IND package to submit to the FDA, which should happen “in the next couple of weeks or so.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.